Rabeprazole

From Self-sufficiency
Jump to: navigation, search
Rabeprazole
240px
240px
Systematic (IUPAC) name
(RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
Legal status
Legal status
Pharmacokinetic data
Bioavailability 52%
Metabolism mostly non-enzymatic,
partly hepatic (CYP2C19)
Biological half-life 1 - 1.5 hours
Excretion 90% renal
Identifiers
CAS Number 117976-89-3
ATC code A02BC04 (WHO)
PubChem CID 5029
DrugBank APRD01212
ChemSpider 4853
Chemical data
Formula C18H21N3O3S
Molar mass 359.444 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex (English pronunciation: /ˈæsɨfɛks/, referring to pH) in the US and Pariet in Australia, Brazil, Canada, Japan, and Russia.

Indications and usage

Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.

  • Gastric ulcer
  • Peptic ulcer disease (PUD)
  • Maintenance of healing of erosive or ulcerative GERD
  • Healing of erosive and ulcerative GERD
  • Healing of duodenal ulcers.
  • Treatment of symptomatic GERD
  • Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
  • Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence

Contraindications

  • hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
  • pregnancy: FDA Pregnancy Ratings: B
  • lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.

Restriction of usage

File:Aciphex-sample-bottle.jpg
Bottle of rabeprazole 20 mg tablets.
  • acute hepatic failure
  • pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)

Side effects

Rabeprazole adverse reactions/side effects include[citation needed]:

Drug interactions

Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).

Overdosage

There is no available data on symptoms of rabeprazole overdose.

Formulations and brand names

Rabeprazole as Rablet (Lupin), AcipHex, Rabeloc, Pariet is supplied in:

Rabeprazole is sold under the brand names Razo, Parit,Rabium and Rablet in India, and Zechin in Pakistan. In the Indian rural market Rabiloz is being marketed by Torrent Pharmaceuticals Ltd.

References

  • Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.
  • Prakash A, Faulds D., Rabeprazole, Drugs. 1998 Feb;55(2):261-7; discussion 268.

External links

es:Rabeprazol

fr:Rabéprazole it:Rabeprazolo sodico pl:Rabeprazol pt:Rabeprazol ru:Рабепразол tr:Rabeprazol